KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to -$1.1 billion.

  • Xenon Pharmaceuticals' Retained Earnings fell 3674.02% to -$1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 billion, marking a year-over-year decrease of 3674.02%. This contributed to the annual value of -$899.5 million for FY2024, which is 3523.02% down from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Retained Earnings stood at -$1.1 billion for Q3 2025, which was down 3674.02% from -$1.0 billion recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Retained Earnings ranged from a high of -$294.3 million in Q1 2021 and a low of -$1.1 billion during Q3 2025
  • Moreover, its 5-year median value for Retained Earnings was -$571.9 million (2023), whereas its average is -$619.3 million.
  • In the last 5 years, Xenon Pharmaceuticals' Retained Earnings crashed by 1443.46% in 2021 and then crashed by 4011.08% in 2023.
  • Xenon Pharmaceuticals' Retained Earnings (Quarter) stood at -$357.4 million in 2021, then plummeted by 35.08% to -$482.7 million in 2022, then crashed by 37.78% to -$665.1 million in 2023, then tumbled by 35.23% to -$899.5 million in 2024, then fell by 26.75% to -$1.1 billion in 2025.
  • Its Retained Earnings stands at -$1.1 billion for Q3 2025, versus -$1.0 billion for Q2 2025 and -$964.5 million for Q1 2025.